From detection to genomic risk interpretation
EditVerity builds integrated experimental and analytical systems to measure genome editing outcomes at high sensitivity and to contextualize which events are neutral vs development-relevant risk.
Our platform spans DNA, chromatin, RNA, and cellular layers—supporting decisions from discovery optimization through IND-enabling safety packages.
What we do
Genome editing programs increasingly face a measurement gap: rare or complex outcomes can be missed, mis-quantified, or reported without functional context. EditVerity provides a platform approach—combining sensitive detection with contextual interpretation—to produce safety intelligence that is actionable and regulatory-ready.
Platform
A modular safety measurement platform that maps editing outcomes, evaluates genome stability, links molecular changes to functional consequences, assesses clonal behavior, and supports immunogenicity assessment—paired with interpretation so results are decision-relevant, not just variant lists.
Off-target profiling
Multiple orthogonal methods for mapping genome-wide off-target edits with high sensitivity.
Chromatin integrity
Structural variant (SV) and genome stability assessment—including chromosomal abnormalities, insertions/deletions, and risks of oncogenicity or insertional mutagenesis.
Functional consequence analysis
On- and off-target consequence profiling across transcriptomic and epigenetic layers to connect outcomes to biological impact.
Clonal fitness & expansion risk
Assessment of clonal expansion and/or unregulated proliferation of edited cells, including longitudinal selection behavior.
Genomic variant interpretation
Not all off-targets are harmful. We integrate multi-layer evidence to distinguish neutral/benign events from functionally or regulatory relevant risk.
Immunogenicity assessment
Assessment of immunogenicity of genome-editing components and expressed transgene(s) using standard analytical approaches.
Applications
We support teams from discovery through translational stages by clarifying risk, mechanism, and decision relevance.
IND / pre-IND safety packages
- High-sensitivity outcome profiling with artifact control
- Genome stability assessment (SVs and chromosomal abnormalities)
- Interpretation and reporting aligned to safety and development questions
Ex vivo programs
- Edited cell products: clonal fitness, stability, and expansion risk
- Outcome profiling across process and timepoints
- Support comparability and release strategy development
In vivo programs
- Sparse and heterogeneous outcome profiling
- Outcome risk mapping across tissues or timepoints (as applicable)
- Decision support for optimization and de-risking
Modality benchmarking
- Controlled comparisons across CRISPR, base editing, and prime editing
- Consistent sensitivity, controls, and interpretation framework
- Support modality selection and parameter optimization
Longitudinal monitoring
- Track stability, selection, and delayed consequences over time
- Evaluate clonal behavior and proliferation advantage signals
- Support durability and comparability strategies
Program decision support
- Translate measurement outputs into decision-relevant insights
- Identify priority risks and evidence gaps
- Provide clear boundaries, assumptions, and limitations
Technology
Our method stack combines sensitive detection, orthogonal validation, and multi-layer consequence profiling—designed to support interpretability and regulatory documentation.
Platform architecture
- Off-target mapping → genome-wide identification of unintended edits
- Genome integrity → SVs, rearrangements, and stability signals
- Consequence profiling → RNA and epigenetic impact where needed
- Clonal fitness → selection and expansion risk over time
- Interpretation → contextual classification and risk tiering
Method stack (examples)
- Off-target analysis methods (genome-wide and targeted)
- Error-suppressed deep sequencing and quantitative frequency estimation
- Structural variant detection and large rearrangement profiling
- Bulk RNA-seq and (when needed) single-cell RNA-seq
- Cut&Tag / ATAC-seq for chromatin and regulatory context
- Clonal tracking and longitudinal selection analysis
Regulatory
We design measurement outputs to be usable in real development settings—clear, traceable, and aligned to safety decision-making.
Reporting framework
- Decision-relevant summaries (not raw variant dumps)
- Context-aware interpretation and risk tiering
- Transparent controls and documented assay boundaries
Validation approach
- Sensitivity, specificity, and reproducibility characterization
- Benchmarking and comparability frameworks
- Clear assumptions, limitations, and data provenance
Company
EditVerity Sciences, Inc. was founded to address a growing gap in genome editing: the lack of reliable, system-level methods to detect and interpret rare and unintended outcomes that can shape safety and translational decisions.
Contact
For scientific or partnership inquiries, please contact us by email.